News
AZ says MPO inhibitor AZD4831 shows promise in heart failure study
AstraZeneca (AZ) has revealed results from a mid-stage study of its investigational myeloperoxidase (MPO) inhibitor in patients with heart failure with preserved ejection fraction (HFpEF).